List of Excipients in Branded Drug DELESTROGEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Par Health USA LLC	DELESTROGEN	estradiol valerate	42023-110	CHLOROBUTANOL
Par Health USA LLC	DELESTROGEN	estradiol valerate	42023-110	SESAME OIL

Delestrogen Excipient Strategy and Commercial Opportunities for Estradiol Valerate Injection

Last updated: September 24, 2026

Delestrogen is an oil-based intramuscular estradiol valerate injection whose commercial differentiation depends more on formulation execution, supply reliability, device design, and regulatory strategy than on surviving composition-of-matter patents. The labeled formulation uses sesame oil as the vehicle and benzyl alcohol as a preservative in multidose presentations.[1] The strongest opportunities are preservative-free unit-dose products, lower-viscosity vehicles, prefilled syringes, improved cold-chain robustness, and generic or 505(b)(2) products that reduce injection burden while preserving the depot pharmacology.

What is Delestrogen and how is it formulated?

Delestrogen contains estradiol valerate, a long-acting ester of estradiol, for intramuscular administration. The labeled strengths are 10 mg/mL, 20 mg/mL, and 40 mg/mL.[1]

Attribute	Delestrogen profile
Active ingredient	Estradiol valerate
Dosage form	Sterile oil-based injectable solution
Route	Intramuscular
Vehicle	Sesame oil
Preservative	Benzyl alcohol in the labeled multidose formulation
Strengths	10 mg/mL, 20 mg/mL, 40 mg/mL
Primary formulation function	Depot release after intramuscular injection
Product category	Small-molecule hormonal injectable
Biosimilar pathway	Not applicable
Principal development issue	Injectable safety, depot performance, preservative and vehicle tolerability

Estradiol valerate is poorly suited to an aqueous formulation without solubilization technology. The oil vehicle dissolves the ester and creates an intramuscular depot. After administration, estradiol valerate is hydrolyzed to estradiol, with release influenced by the oil phase, injection volume, tissue dispersion, and ester hydrolysis.[1]

The commercial product’s excipient system is intentionally simple. That simplicity can reduce formulation risk, but it also leaves several potential weaknesses: sesame allergy concerns, injection discomfort, multidose-container contamination risk, benzyl alcohol exposure, relatively high viscosity, and dependence on oil quality and sterile filling controls.

What excipients are used in Delestrogen?

The key excipients are sesame oil and benzyl alcohol. Sesame oil is the principal vehicle. Benzyl alcohol functions as an antimicrobial preservative in the multidose presentation.[1]

Sesame oil

Sesame oil provides solubilization and depot-forming behavior. Its advantages include established parenteral use, adequate solvent capacity for lipophilic steroid esters, and a long history in intramuscular hormone products.

Its commercial limitations include:

• Potential concern for patients with sesame sensitivity.
• Batch-to-batch variation in fatty-acid composition and oxidative stability.
• Higher viscosity than some medium-chain triglyceride vehicles.
• Possible injection-site pain or induration.
• Sensitivity to light, oxygen, and storage conditions.
• A need for tight control of peroxide value, acid value, water content, and particulate matter.

A replacement vehicle would need to preserve estradiol valerate solubility, chemical stability, sterility, syringeability, depot behavior, and acceptable local tolerability. A vehicle that lowers viscosity but accelerates drug release may change exposure and require a new clinical or pharmacokinetic justification.

Benzyl alcohol

Benzyl alcohol supports multidose-container preservation but introduces a separate safety and product-positioning issue. Parenteral benzyl alcohol exposure is particularly relevant to neonates and young infants, although Delestrogen is generally used in adult hormonal therapy. A preservative-free presentation would remove benzyl alcohol from the formulation and improve positioning for patients or institutions seeking to minimize excipient exposure.

Removing benzyl alcohol is not automatically a generic substitution. The applicant would need to demonstrate container-closure integrity, microbial control, sterility assurance, in-use handling, and appropriate labeling for single-dose or limited-use administration.[2]

What excipient strategy offers the best commercial opportunity?

The highest-value strategy is to separate the product into two development paths: a low-risk generic path that preserves the established formulation and a differentiated path that changes the vehicle, container, concentration, or administration system.

Strategy	Commercial benefit	Main regulatory burden	Opportunity level
Sesame-oil generic	Lower development cost and familiar formulation	ANDA sameness and injectable quality requirements	High
Preservative-free single-dose vial	Removes benzyl alcohol and reduces multidose concerns	Sterility, container closure, packaging and handling data	High
Prefilled syringe	Reduces preparation steps and dosing error	Device, compatibility, extractables and leachables	High
Lower-viscosity oil vehicle	Easier injection and potentially better patient experience	Pharmacokinetic and local-tolerability comparability	Medium-high
Higher-concentration product	Lower injection volume	Solubility, precipitation and local tolerability	Medium
Sustained-release depot	Longer dosing interval	New clinical, PK and local safety package	Medium, higher risk
Aqueous or emulsion formulation	Potentially different administration profile	Major formulation and clinical development burden	Low to medium
Ready-to-use clinic kit	Workflow and administration value	Packaging and combination-product considerations	Medium

A preservative-free, single-dose product is likely the most practical differentiated opportunity. It retains the known estradiol valerate active ingredient and intramuscular route while addressing a clear formulation concern. The product could use a small-volume vial or prefilled syringe with a validated oxygen and moisture barrier.

Which alternative excipients could replace sesame oil?

Potential vehicle candidates include medium-chain triglycerides, refined vegetable oils, ethyl oleate, benzyl benzoate-containing systems, and other established parenteral solvents. Each candidate has different regulatory and technical implications.

Medium-chain triglycerides

Medium-chain triglyceride vehicles may offer lower viscosity and improved injection characteristics compared with some fixed vegetable oils. The key development questions are estradiol valerate solubility, precipitation during storage, depot duration, oxidative stability, and local tissue tolerance.

The formulation should be screened across temperature excursions, freeze-thaw exposure, agitation, and extended storage. A lower-viscosity formulation may be commercially attractive, but faster drug diffusion from the injection site could produce a different exposure profile.

Ethyl oleate

Ethyl oleate can improve solubilization for some lipophilic compounds and may reduce viscosity. Its use would require close control of oxidative degradation and compatibility with elastomeric closures, syringe components, and needle systems.

Benzyl benzoate-containing systems

Benzyl benzoate can increase solvent capacity but may raise local tolerability and excipient-justification issues. It would be more relevant to a concentrated or low-volume formulation than to a simple generic product.

Mixed vehicles

A mixed vehicle could balance solubility, viscosity, and depot duration. The disadvantage is higher formulation complexity and a greater need to demonstrate control of composition, phase behavior, degradation products, and injection-site tolerability.

What formulation patents protect Delestrogen?

Public commercial protection for Delestrogen is unlikely to depend on an enforceable modern formulation patent. Estradiol valerate is an established small molecule, and the basic oil-based injectable concept is old. Any historic patents covering the active ingredient, conventional ester chemistry, or broad oil solutions would generally be expected to have expired or to provide limited practical exclusivity.

The relevant intellectual-property categories are:

1. Estradiol valerate composition-of-matter patents.
2. Manufacturing methods for esterification, purification, and crystallization.
3. Injectable oil compositions.
4. Preservative-free packaging systems.
5. Prefilled syringe and needle assemblies.
6. Extended-release depot formulations.
7. Methods of treating menopausal symptoms, hypogonadism, or gender dysphoria.
8. New dosing regimens and patient-selection claims.

The last four categories could support new patent filings if they contain a technically specific and non-obvious improvement. A broad claim to estradiol valerate in oil is less likely to provide durable protection than claims tied to a defined vehicle ratio, impurity profile, release characteristic, concentration, container system, or dosing schedule.

What is the Orange Book status of Delestrogen?

The Orange Book is relevant because it identifies approved drug products, reference-listed drugs, patents, and exclusivity information used in abbreviated new drug applications.[2] Delestrogen’s practical regulatory value depends on the status of the underlying reference product and the availability of an FDA-designated reference-listed drug.

For a prospective generic applicant, the central questions are:

• Whether an active reference-listed drug is available.
• Whether the reference product is listed as eligible for ANDA referencing.
• Whether FDA has identified product-specific guidance.
• Whether listed patents or exclusivity remain active.
• Whether the applicant must use an ANDA or a 505(b)(2) application.

An old product with limited or uncertain commercial availability can create regulatory and commercial friction even when patent protection is weak. FDA approval status, marketing status, and commercial availability are separate issues. A product can have an approved label while experiencing discontinuation, intermittent supply, or limited distribution.

When does Delestrogen lose exclusivity?

The principal market-entry conclusion is that Delestrogen is not protected by a new-product exclusivity period comparable to a recently approved chemical entity. The active ingredient and conventional dosage form are longstanding. The remaining barriers are more likely to involve reference-product selection, regulatory data requirements, manufacturing capability, quality systems, and market size than basic patent exclusivity.

A generic applicant should assess:

Exclusivity issue	Likely relevance
New chemical entity exclusivity	Not relevant to longstanding estradiol valerate
Five-year NCE exclusivity	Not expected to apply
Three-year clinical-investigation exclusivity	Possible only for qualifying later approval changes
Pediatric exclusivity	Product-specific and requires verified FDA records
Orphan-drug exclusivity	Indication-specific and not inherent to the product
Patent term extension	Unlikely to create current protection for the old product
Formulation patent term	Must be checked against current Orange Book listings
Method-of-use patents	May affect labeled indications but generally do not block all uses

No reliable commercial conclusion should be based on an assumed expiration date without checking current Orange Book records, FDA approval history, and patent listings. The main opportunity is therefore a regulatory and formulation execution opportunity, not a patent-expiration trade.

Are there Paragraph IV challenges for Delestrogen?

A Paragraph IV certification is relevant only if a generic applicant is referencing an FDA-listed drug with a patent listed in the Orange Book. The applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed.[2]

For Delestrogen, the practical Paragraph IV risk appears limited if no active formulation or method-of-use patents are listed against the relevant reference product. The litigation risk could still arise from:

• A newly listed patent covering a delivery system.
• A later-approved preservative-free or concentrated formulation.
• A method-of-use patent directed to a protected indication.
• A patent dispute over a new depot or prefilled-syringe product.

A conventional sesame-oil generic would generally face lower patent risk than a differentiated product that copies a patented device, vehicle ratio, or dosing profile.

Which companies could challenge or compete with Delestrogen?

Competition can come from three groups:

Generic injectable manufacturers

Sterile injectable companies with experience in oil-based products are the most natural entrants. Their advantages include existing aseptic manufacturing, analytical methods, regulatory infrastructure, and hospital or specialty-pharmacy distribution.

Hormone-therapy manufacturers

Companies selling estradiol patches, gels, tablets, pellets, and other injectable hormone products can compete for the same clinical demand even without copying Delestrogen. Transdermal products may be preferred where avoidance of intramuscular injections is important.

Compounding pharmacies

Compounded estradiol valerate injections can create local price and availability competition, but compounded products do not provide the same FDA-approved product status, quality oversight, or nationwide commercial consistency as an approved generic.[3]

The commercial winner would likely combine reliable supply with a delivery advantage. A basic generic can capture price-sensitive demand. A preservative-free syringe or lower-pain formulation can support premium positioning.

What generic launch scenarios exist for Delestrogen?

Scenario 1: Conventional generic

The applicant duplicates the established concentration range, sesame-oil vehicle, preservative system, route, and container configuration. This is the lowest-risk route if the reference product and regulatory pathway are available.

Commercial strengths include lower development cost and familiar clinical use. Weaknesses include limited differentiation and price competition.

Scenario 2: Preservative-free unit dose

The applicant develops a single-dose vial or prefilled syringe without benzyl alcohol. This could command a modest premium in clinics and specialty practices that value reduced handling and excipient minimization.

The key barriers are sterile manufacturing, container closure, in-use stability, and packaging cost.

Scenario 3: Lower-viscosity injectable

A medium-chain triglyceride or other alternative vehicle could improve syringeability and injection comfort. The product would require a stronger comparability package because vehicle changes can affect absorption and local tolerability.

Scenario 4: High-concentration product

A 40 mg/mL or higher-strength product could reduce injection volume. Higher concentration increases the risk of precipitation, injection-site reactions, and formulation instability. It may be commercially useful where dosing volumes are a significant treatment burden.

Scenario 5: Extended-release depot

A long-acting formulation could reduce administration frequency, but it would move the product toward a higher-risk 505(b)(2) or new-drug development program. Clinical pharmacokinetics, local tissue safety, dose reversibility, and management of supratherapeutic exposure would be central issues.

How strong is the Delestrogen patent estate?

The patent estate for the legacy product is likely weak as a barrier to a conventional generic. The stronger intellectual-property opportunity lies in newly created formulation and device claims.

IP area	Relative strength for a new entrant
Estradiol valerate molecule	Low, due to age of the active ingredient
Conventional sesame-oil formulation	Low
Benzyl alcohol preservation	Low
Defined impurity and oxidation-control profile	Medium
Preservative-free packaging	Medium
Prefilled syringe system	Medium to high
Novel low-viscosity vehicle	Medium to high
Extended-release depot technology	High if clinically validated
New dosing regimen	Medium, depending on claim scope and evidence
Manufacturing process	Medium if it improves purity, yield, or stability

A new entrant should avoid relying on a broad formulation patent as its only protection. Device patents, trade secrets covering sterile filling and impurity control, manufacturing know-how, and customer contracts can provide more practical protection.

What manufacturing and IP barriers affect commercial entry?

The main manufacturing barrier is sterile production of an oil solution with consistent potency, impurity control, particulate performance, and container compatibility. The active ingredient is not difficult because of biological complexity, but the dosage form is less forgiving than an oral tablet.

Critical quality attributes include:

• Assay and content uniformity.
• Estradiol valerate-related impurities.
• Hydrolysis and oxidation products.
• Peroxide and acid values in the oil vehicle.
• Particulate matter.
• Sterility and endotoxin control.
• Extractables and leachables.
• Viscosity and syringeability.
• Container-closure integrity.
• Stability under light, heat, and agitation.

A manufacturer with an established sterile oil-filling line has a material advantage. New entrants may need to contract with a qualified injectable manufacturer, which can create capacity, technology-transfer, and supply-assurance risk.

What licensing deals could support a Delestrogen strategy?

A commercial program could use several licensing structures:

1. License a sterile injectable manufacturing platform from a contract development and manufacturing organization.
2. Acquire rights to a low-viscosity parenteral vehicle with prior FDA-use history.
3. License a prefilled-syringe or needle-safety system.
4. Partner with a specialty distributor serving hormone-therapy clinics.
5. Co-develop a preservative-free product with a manufacturer that already markets estradiol therapies.
6. License an extended-release depot platform and pursue a 505(b)(2) application.

The most defensible deal structure would link milestone payments to formulation selection, FDA meeting outcomes, approval, and commercial launch rather than paying primarily for broad platform rights.

What is the revenue exposure and competitive outlook?

The revenue opportunity is likely niche rather than mass-market. Estradiol valerate injection competes with transdermal estradiol, oral estradiol, estradiol cypionate, pellets, and compounded products. Demand can still be commercially meaningful where patients or clinicians prefer injectable administration, where transdermal adherence is poor, or where supply disruptions create substitution demand.

Revenue potential depends on:

• Approved indication and prescribing environment.
• Product availability and shortage conditions.
• Generic price erosion.
• Payer coverage.
• Specialty-pharmacy access.
• Clinic administration economics.
• Product concentration and injection volume.
• Supply reliability.

A conventional generic is likely to face rapid price compression if multiple sterile-injectable entrants appear. A differentiated preservative-free syringe, however, could retain better margins if it solves preparation, excipient, or administration problems without requiring a wholly new clinical profile.

Key Takeaways

• Delestrogen uses estradiol valerate in sesame oil, with benzyl alcohol in the labeled multidose formulation.[1]
• The legacy product is unlikely to have meaningful current exclusivity based on the active ingredient or conventional oil formulation.
• The most practical opportunity is a preservative-free single-dose vial or prefilled syringe.
• Medium-chain triglyceride and other lower-viscosity vehicles could improve administration but require comparability and local-tolerability work.
• A basic generic is commercially feasible but vulnerable to rapid price erosion.
• A new depot or extended-release formulation offers stronger differentiation but carries materially higher regulatory and clinical risk.
• Orange Book status, reference-product availability, and current patent listings must control the ANDA or 505(b)(2) strategy.[2]
• No biosimilar pathway applies because estradiol valerate is a small-molecule drug.
• Sterile oil filling, oxidation control, container compatibility, and reliable supply are the principal execution barriers.
• The strongest IP opportunity is in formulation, packaging, device, dosing, and manufacturing claims created by a new product.

FAQs About Delestrogen Excipient and Commercial Strategy

Can sesame oil be replaced in a Delestrogen generic?

Yes, but a replacement vehicle may alter solubility, release, injection-site tolerability, and pharmacokinetics. A conventional ANDA strategy is generally simpler when the formulation remains closely aligned with the reference product.

Is a preservative-free Delestrogen product commercially attractive?

Yes. A single-dose vial or prefilled syringe could address benzyl alcohol exposure, multidose handling, and clinic workflow. The product would need robust sterility and container-closure controls.

Does Delestrogen have biosimilar competition?

No. Estradiol valerate is a small-molecule active ingredient. Competition would come through generic, 505(b)(2), branded reformulation, transdermal, oral, pellet, or compounded products.

Could a higher-strength estradiol valerate injection obtain patent protection?

Potentially. Patentability would depend on more than concentration alone. Stronger claims would link concentration to defined solubility, stability, injection volume, pharmacokinetic performance, or improved tolerability.

What is the best commercial product concept for a new entrant?

A preservative-free, low-volume, prefilled intramuscular syringe using a well-characterized oil vehicle is the most balanced concept. It offers meaningful differentiation while avoiding the clinical complexity of a wholly new long-acting depot.

References

1. DailyMed. (n.d.). Delestrogen: Estradiol valerate injection, USP prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2023). Human drug compounding progress report.